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Background: Interstitial lung diseases (ILDs) in children represent a heterogeneous group of rare respiratory
disorders that affect the lung parenchyma. After the launch of the French Reference Centre for Rare Lung Diseases
(RespiRareW), we created a national network and a web-linked database to collect data on pediatric ILD.
Methods: Since 2008, the database has been set up in all RespiRareW centres. After patient's parents' oral consent is
obtained, physicians enter the data of children with ILD: identity, social data and environmental data; specific
aetiological diagnosis of the ILD if known, genetics, patient visits to the centre, and all medical examinations and
tests done for the diagnosis and/or during follow up. Each participating centre has a free access to his own
patients' data only, and cross-centre studies require mutual agreement. Physicians may use the system as a daily aid
for patient care through a web-linked medical file, backed on this database.
Results: Data was collected for 205 cases of ILD. The M/F sex ratio was 0.9. Median age at diagnosis was 1.5 years
old [0–16.9]. A specific aetiology was identified in 149 (72.7%) patients while 56 (27.3%) cases remain undiagnosed.
Surfactant deficiencies and alveolar proteinosis, haemosiderosis, and sarcoidosis represent almost half of the
diagnoses. Median length of follow-up is 2.9 years [0–17.2].
Conclusions: We introduce here the French network and the largest national database in pediatric ILDs. The
diagnosis spectrum and the estimated incidence are consistent with other European databases. An important
challenge will be to reduce the proportion of unclassified ILDs by a standardized diagnosis work-up. This database
is a great opportunity to improve patient care and disease pathogenesis knowledge. A European network including
physicians and European foundations is now emerging with the initial aim of devising a simplified European
database/register as a first step to larger European studies.
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Interstitial lung diseases (ILDs) in infants and children
represent a heterogeneous group of rare and complex
respiratory disorders that affect the parenchymal part of
the lung, and are mostly chronic [1].
Disease complexity is reflected by the various underlying
mechanisms initiated by the primary causes of injury. As a
result, a major concern is the difficulty to define and to
identify ILDs in children and especially in infants. A
rigorous analytical process is required to explore correlation
between pathological determinants and patient’s pheno-
types, which in turn is essential to progress in disease
classification and understanding.
ILDs are considered as rare diseases. In a growing
number of countries worldwide, rare diseases have been
recognized as a crucial health issue, and strategies are
developed to implement appropriate public policies for
patient care and research. In France, rare diseases have
also been identified as a priority of public health needs,
and among the various actions launched; a National
Reference Centre for Rare Lung Diseases (RespiRareW,
www.respirare.fr) was created in 2006 to care for all chil-
dren in the country suspected or known to have one of
them, including ILDs. The main objective of RespiRareW
is to establish disease cohorts based on aggregation of
patients followed over time, through a national
organization with affiliated centres that was set up to
cover the entire French pediatric population with
respiratory diseases. For ILDs, a platform was built to
provide appropriate resources to pediatricians to record
patient information and to ensure prospective clinical data
collection. After data standardization and monitoring for
quality control, data is stored into a national ILD database
through a web interface. The RespiRareW platform, which
combines clinical, biological, functional and genetic
information, is a unique national structure for the
emergence of prospective registries and databases allowing
the development of epidemiological, clinical and transla-
tional research studies.
Information provided herein describes the ILD database
of the RespiRareW platform. Analyses of the data currently
included are presented, as well as the potential for
international collaborative studies.
Materials and methods
Database structure and quality control
The RespiRareW database structure for rare respiratory
diseases was created to include extensive information on all
forms of rare lung diseases grouped within four main cat-
egories: ILD, respiratory malformations, ciliary dyskinesia,
and other rare diseases with chronic respiratory insuffi-
ciency. Data from patients is entered via a secured Internet
protocol into a safe database through a web interface. The
interface is visible from the web through the https secureprotocol, on a DMZ network. It uses the LAMP system,
with a MySQL database for data storage; PHP scripts
interface for access to database, as well as a Apache 2
webserver. The structure is hosted on Linux servers, within
the secure server network of Paris-6 University Pierre et
Marie Curie (UPMC), the coordinator affiliated institution.
The database server hosting the MySQL server is behind a
firewall, linked to the webserver through a secure encrypted
IP to IP tunnel. Access to the patient is filtered through a
central identification number. Database and data collection
have been approved by the French national data protection
authorities: “Commission Nationale de l’Informatique et
des Libertés” and the “Comité Consultatif sur le Traitement
de l'Information en matière de Recherche dans le domaine
de la Santé”.
The Reference centre and 8 affiliated centres in university
hospitals (called Competence Centres) are spread all
around the French national territory. Each of them covers a
French area with a local network of affiliated centres
(Additional file 1). Every participating centre only has
access to their own patients’ data. For cross-centre studies,
the respective centres must agree explicitly to share its
anonymous data with other centres. A charter describes the
rules, including general rules relating to organization and
rules governing access to data. Each participating member
is asked to accept the charter of good use. To access the
database, users receive a personal user name and password.
Users can see who modified the file, and if any modification
is observed in data recording, a tracking system is available
to get back to a previous version of the data. Patients must
give their oral informed consent before their data is
included into the database.
The quality of the data relies on the users who enter
the data, and on a database scientific committee who
regularly reviews proposed cases for inclusion. The
RespiRareW administration offers each centre a specific
training for proper use of the on-line database. A data
manager and a technical team are in charge of quality
control, monitoring for data coherence, absence of
duplicates, and transfer of data if needed. The data is
organized in a data warehouse to optimize data
visualization and data retrieval.
To maintain motivation and to ensure long-term in-
volvement of all participants, specific contacts with the
coordinating team through e-mail, phone calls and local
visits have been put in place. In addition, an annual
meeting is organized with all affiliated centres.
Data collection and analysis
The database we have created at the national level in
France was elaborated by a team composed of clinicians
and databank professionals, using data modelling techni-
ques and methodologies with a Conceptual Data Model
(CDM) providing a view of the key data entities and
Table 1 Interstitial lung diseases diagnoses proposed in
the database
Exposure related ILD Hypersensitivity pneumonitis
Aspiration pneumonitis











- Anti-glomerular basement membrane
disease









Familial hypercalcemia with hypocalciuria
Others



















ILD specific to infancy Pulmonary glycogenosis
Neuroendocrine cell hyperplasia of infancy
ILD with no diagnosis
Nathan et al. Orphanet Journal of Rare Diseases 2012, 7:40 Page 3 of 11
http://www.ojrd.com/content/7/1/40their relationships (Additional file 2). The RespiRareW
database is structured as medical record for patients.
Users can document a large amount of data: identity,
social data, environmental data, and diagnosis of the
ILD if known, genetic data, patients visits to the centre,
and the entire medical examinations and tests done for
the diagnosis or the follow up of the patient. Data can
be entered at every visit of the patient or at least once a
year in a minimal dataset containing an “annual form”
and a “diagnosis form”, which is filled at the first visit
and can be updated at any time (Additional file 3). The
datasets for the 3 other disease groups (respiratory
malformations, ciliary dyskinesia, and other rare diseases
with chronic respiratory insufficiency) are organized in a
similar way, with a diagnosis dataset and a follow-up
dataset (on an annual basis). A common list of items for
all groups includes clinical, functional, imaging, organ
specific tests, treatments and outcome information.
Extended disease-specific datasets contain information
relevant to each group of rare diseases. The entire ILD
French database dictionary is provided in the Additional
file 4. These extended datasets have been defined by
steering committees composed of experts in the respect-
ive groups of diseases. They are implemented continu-
ously in order to provide extensive and detailed
documentation of a given disease. The database also
offers a system for inclusion of biological, microbio-
logical, radiographic, histological, cytogenetic, molecular
and genetic information.
The database is designed for a long-term use. In this view,
the interface has been developed so that it is easy to use
and friendly, with rolling menus and data entry forms
accessible to unskilled users. In addition, RespiRareW
database has been organized and structured as a medical
record for patients. Consequently, physicians can use the
system as a daily aid for patient care through a web
accessible medical record backed on this database. It takes
around 20 minutes to fill the form at the first visit and
around 5 minutes at every additional visit.
ILD Patients
Based on our previously described ILD classification
(Clement et al. Orphan J Rar Dis 2010), all patients
eligible to one of the ILD diagnosis can be proposed for
inclusion in the database (Table 1). Moreover, if no diag-
nosis is known, any patient under 18 years old with a
persistent interstitial pathway on CT-scan can also be
included in the database. Acute interstitial diseases are
not included. The diagnosis is based on clinical, radio-
logical, and functional features, including tachypnea,
diffuse infiltrates on chest imaging and impaired gas
exchange. Written information is given to the patient/
family before documenting the database. The physician
of the Competence Centre in charge can recommend
MaleFemale
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Figure 1 Age at diagnosis of interstitial lung disease according
to sex.Results
Pediatric ILD patients
The RespiRareW database was launched in September
2008. The database was set up at the end of 2008. After
their initial training, centres started to include patients
one by one. At the beginning, after the database
committee validation, centres included all patients with
ILD less than 18 years old currently followed in the
centres, with their entire past medical records. New
patients were also included in the database in a
prospective way. Thus, the database covers up to 17 years
for some patients followed for a long time at the time of
the database creation. This is an on-going process, and
centres’ ability to propose patients for inclusion in the
database is still variable in terms of speed. Multiple
biases, such as recovered or deceased patients, cannot
let us talk yet about prevalence or incidence.
At the present time, 217 patients were proposed for
inclusion in the database. The database committee
rejected 12 patients because the diagnosis of ILD wasn’t
proven, or because insufficient data was provided. Thus,
the number of ILD patients included in the database is
now 205.
The study is presented to all patients/families during a
medical visit. None of the family has refused to be
enrolled. Of importance also is the observation that
many physicians in charge of the patients consider this
structured data collection of great help. Indeed, as
mentioned above, in an increasing number of French
pediatric pulmonology teams, RespiRareW database is
now used as a medical record for patient care.Sex and age distribution
Considering the 205 ILD children entered in the
database, the sex ratio is 0.9 boy/girl. The median age at
diagnosis is 1.5 years old [0–16.9]. More than half of
ILD start before 2 years old (Figure 1). Median
diagnostic delay is 1 year [0–12.6], largely influenced by
the type of ILD. The median length of follow up into the
database is currently 2.9 years [0–17.2].Diagnosis distribution
Aetiology for the ILD has been identified for 149 (72.7%)
patients whereas 56 (27.3%) patients remain with no
identified cause. Surfactant deficiencies and alveolar
proteinosis, haemosiderosis and sarcoidosis, represent
almost half of the diagnoses. The diagnosis breakdown,
age at diagnosis, sex ratio and length of follow up are
detailed on Table 2.Surfactant disease and alveolar proteinosis
For 36 children (17.5%), a surfactant disorder has been
identified. These children have an early median age of
diagnosis (0.3 year-old). Pulmonary surfactant-associated
protein C gene (SFTPC), Pulmonary surfactant-associated
protein B gene (SFTPB), ATP-binding cassette subfamily A,
member 3 gene (ABCA3), and Thyroid transcription factor-
1 gene (TITF1=NKX2-1) mutations were found (Table 3).
SFTPC mutations are the most frequent genetic
abnormalities (22 patients), representing 10.7% of all
ILD patients. The recurrent mutation I73T represents
two thirds of them. The median age at diagnosis is
6 months [0–8.5]. Lung biopsy was performed for 14
children, showing an alveolar wall thickening, type 2
alveolar epithelial cells hyperplasia, inflammation cells
infiltration with or without macrophagic intra-alveolar
accumulation with cholesterol crystals and occasionally
fibrosis. All patients received steroids. Among them,
nineteen patients underwent intravenous steroid pulses
and azithromycin. Two patients died at 3 and 17 years
old. Seven patients presenting neonatal respiratory
distress had SFTPB homozygous mutations. All of them
died before 2 months of life. ABCA3 homozygous
mutation was found in 5 patients with neonatal
respiratory failure. Median age at diagnosis was 0.3 years
old [0-12.3]. They all needed long-term steroid pulses.
Two patients showed a brain lung thyroid syndrome
with TITF1/NKX2-1 mutation. One of them died at
month 18.
Twenty patients were diagnosed with alveolar
proteinosis (sex ratio = 1.9 boy/girl). Onset of symptoms
was very early with a median age at diagnosis of 7 months.
Most of them needed therapeutic broncho-alveolar
lavages (BAL).
Table 2 Aetiologic spectrum of interstitial lung disease (ILD) in children
Diagnoses Patients (n=) Patients (%) Sex ratio M/F Median age at diagnosis (years) Range
Surfactant disorders 36 17.6 1.0 0.3 (0–12.3)
Haemosiderosis 23 11.2 0.3 4.8 (0.7-14)
Granulomatous diseases (sarcoidosis) 21 10.2 1.0 9.6 (5.6-14.4)
Alveolar proteinosis 20 9.7 1.8 0.6 (0–13.6)
Exposure diseases 9 4.4 0.8 10.6 (2.2-14.4)
Connective disorders and vascularitis 9 4.4 0.6 12.4 (0.1-15.7)
Metabolic disorders 5 2.4 0.7 1.7 (0–4)
Langerhans' cell histiocytosis 5 2.4 1.5 1.1 (0.5-7.3)
Infectious diseases 4 2.0 1.0 0.2 (0–6.6)
Eosinophilic lung diseases 4 2.0 1.0 10.0 (5.1-16.9)
Lymphatic disorders 4 2.0 0.3 0 (0–14.5)
Others 9 4.4 2.0 1.3 (0–12.8)
Undiagnosed 56 27.3 1.0 0.7 (0–16.4)
Total 205 100 0.9 1.5 (0–16.9)
Abbreviations: M: male; F: female.
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We collected data of 23 haemosiderosis (Table 4). There
was a large predominance of girls (18 vs. 5 boys) and the
median age at diagnostic was 4.8 years old [0.7-14]. Three
of them were associated with another disease (cow proteins
milk allergy, celiac disease, Down syndrome). Initial presen-
tation was mainly acute with haemoptysis and major
anaemia but some cases were more difficult to diagnose
with cryptic chronic bleeding and no haemoptysis.
Pulmonary hypertension was reported for only 2 children.
Nine children underwent open lung biopsy or transbron-
chial biopsy to confirm the diagnosis. All children benefits
from a steroid treatment, with steroid pulses for 11 of them.
Four patients benefit from supplemental treatment by
hydroxychloroquin and 4 from mycophenolate mofetil.
Sarcoidosis
Twenty-one children had interstitial granulomatous lung
disease, which was for all of them a sarcoidosis (Table 5).
Sex ratio was 1 boy/girl and median age at diagnosis was
9.4 years old. Sarcoidosis is one the most frequent pre-
teenager ILD diagnosis with connective lung diseases
and exposure related ILD. BAL was performed for 15 of
them and showed in most of the cases a lymphocytic
infiltration. CD4/CD8 ratio was available for 7 patients
and was >1 for 6 of them. Five patients underwent
transbronchial or open lung biopsy to assert diagnosis.
All patients were treated with steroids and among them,
11 received steroid pulses.
Other diagnosis
Nine children had exposure related ILD: 5 had hypersen-
sitivity pneumonitis (turtledove, pigeon, straw), 1 wasdue to total body irradiation, and the causal agent was
not specified for the others. Outcomes were good with
no residual symptoms after eviction and, for some of the
patients, short steroid therapy.
Connective lung diseases were diagnosed for 9 children
(rheumatoid arthritis, systemic sclerosis, mixed connective
tissue disease). Three children presented with vasculitis of
unknown origin. No capillaritis has been included in the
database at this time. All together, there are twice as many
girls than boys and teenagers are largely represented, but 3
children were diagnosed before 5 years old.
ILD related with metabolic disorders were diagnosed
for 5 children. Among them, 4 had a Niemann-Pick B or
C disease and one had a Cobalamine C deficiency.
Five children had Langerhans’ cell histiocytosis with
ILD. All but one had a multifocal disease with bone
involvement.
Infectious diseases leading to ILD was diagnosed for 4
children and attributed to Chlamydiae trachomatis for 2
of them. All of them were free of symptoms at the end
of the follow up (after 6 month to 3 years).
We also collected data for 4 eosinophilic lung diseases
and 4 lymphatic disorders.
Nine children presented an ILD related to others
diagnosis: Crohn disease (n = 1), inhalations (n = 1),
alpha-1-antitrypsin deficiency (n=1), xanthogranulomatous
disease (n=1), constrictive bronchiolitis (n=1), hamartoma
(n=2), others (n=2).No diagnosis
Finally, out of 205 patients presenting with ILD, 56 children
(27.3%) remained with no diagnosis (Additional file 5). Sex
ratio is 1 male/female and median age at diagnosis is young:
Table 3 Characteristics of patients with surfactant disorders
Patient number Sex Age at diagnosis (years) Follow up (years) Surfactant disorder Mutation
1* M 0.3 2.9 SP-C c.424delC
2* M 0.4 3.6 SP-C c.566 G>A (C189Y)
3* F 0.3 3.8 SP-C c.566 G>A (C189Y)
4* M 0.2 1.4 SP-C c.325-1 G>A
5* M 2.4 0.4 SP-C c.218 T>C (I73T)
6* F 5.8 0 SP-C c.218 T>C (I73T)
7* F 1.6 2.4 SP-C c.218 T>C (I73T)
8* F 0.4 1.4 SP-C c.218 T>C (I73T)
9* F 1.2 1.2 SP-C c.218 T>C (I73T)
10* M 0.8 2.5 SP-C c.218 T>C (I73T)
11* F 0.3 4.2 SP-C c.218 T>C (I73T)
12* F 0 1.8 SP-C c.218 T>C (I73T)
13* M 1.6 md SP-C c.218 T>C (I73T)
14* M 0.7 4.2 SP-C c.218 T>C (I73T)
15* M 2.2 3.1 SP-C c.218 T>C (I73T)
16* F 0.2 6.2 SP-C c.218 T>C (I73T)
17* F 2.7 11.7 SP-C c.218 T>C (I73T)
18* F 0.5 12.4 SP-C c.218 T>C (I73T)
19* M 0.4 6.6 SP-C c.218 T>C (I73T)
20* M 0.3 2.4 SP-C c.581 T>C (L194P)
21* M 8.5 0 SP-C c.563 T>C (L188P)
22* F 0.4 17.2 SP-C c.116 T>C (V39A)
23 M 0 0.1 SP-B g.1549 C>GAA (121ins2) −/−
24 M 0 0.1 SP-B g.1549 C>GAA (121ins2) −/−
25 M 0.2 0 SP-B g.1549 C>GAA (121ins2) −/−
26 F 0 0.2 SP-B g.1549 C>GAA (121ins2) −/−
27 M 0.1 0 SP-B c.496delG −/−
28 M 0 0.1 SP-B Y253X −/−
29 F 0 0.2 SP-B 672+ 2del5 −/−
30* F 0 9.2 ABCA3 c.3518 C>G (T1173R) −/−
31* M 0.3 10.9 ABCA3 c.757 G>C (D253H) −/−
32* F 2.3 MD ABCA3 c.3518 C>G (T1173R) −/−
33* M 0.3 3.4 ABCA3 P585 −/−
34* F 12.3 3 ABCA3 c.3518 C>G (T1173R) −/−
35* F 0.1 4.8 TTF1 c.786_787del2 (p.L263fs)
36* F 0.1 1.5 TTF1 c.493 C> T(R165W)
Sex ratio 1 Median 0.3 Median 2.4
* Published patients.
Abbreviations: M: male. F: female. MD: missing data.
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34.5% of children with ILD diagnosed before 2 years old re-
main with no diagnosis whereas it is so for 19.1% of ILD
diagnosed after 2 years old. For a large part of them, the
absence of diagnosis was concluded after a number ofinvestigations, including genetic studies (n=40) and BAL
(n=27). Only 22 of them underwent lung biopsy. However,
some patients did not benefit from these explorations, or
are missing data, so that the absence of diagnosis cannot be
ascertained.
Table 4 Characteristics of haemosiderosis patients
Patient
number






1 F 2.3 1.3 BAL and LB
2 M 1.4 15.6 BAL and LB
3 F 3.2 13.2 BAL and LB
4 M 1.1 13.7 BAL and LB
5 M 5.4 9.8 BAL
6 F 7.2 10.8 BAL and LB
7 F 6.7 7.4 BAL
8 F 4.7 7.3 BAL and LB
9 F 12.3 MD MD
10 F 4.8 2.3 BAL
11 F 10.6 5.8 BAL
12 F 5.1 4.8 BAL
13 M 1.4 4.6 BAL
14 F 7.2 4.7 BAL
15 M 14 3.8 BAL
16 F 0.8 2 BAL
17 F 0.7 2.6 BAL and LB
18 F 1.9 3.5 BAL and LB
19 F 7.2 0.6 BAL
20 M 2.3 2.7 BAL
21 F 1.9 MD BAL and LB
22 F 6 MD MD
23 F 11.6 0.5 BAL
Total Sex ratio
0.3
Median 4.8 Median 4.7 BAL=21
LB=9
* Published patients.
Abbreviations: M: male. F: female. MD: missing data. BAL: broncho-alveolar
lavage. LB: lung biopsy.
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In the present article, we describe the first national
internet-based patient database for pediatric ILD.
Analysis of the collected data provides information on
the current diagnosis distribution of these heterogeneous
disorders.
The need for a centralized database was clearly
identified, with the main concern being how to build
its infrastructure. Indeed, the system would have to
serve clinicians treating the patients, researchers for
conducting national and international programs,
epidemiologists to gather demographic data, patients
and their families seeking accurate information on
their disease, as well as the pharmaceutical industry
expressing increased interest for rare disease
databases. At the present time, the system includes
personal/demographic data and clinical information.As for other patient registries and central databases,
the major challenge is data standardization and quality.
Data quality is the cornerstone of the registry system,
and we are extremely focused on quality control and
data accuracy. As indicated above, the RespiRareW
system is headed by the reference centre in close con-
nection with the affiliated centres in French university
hospitals. After several months of development, involve-
ment of affiliated centres is increasing. To ensure data
quality, an intensive monitoring has been organized with
the coordinating team and a database committee, that
review all cases proposed for inclusion in the database.
To facilitate switch from usual paper-based documenta-
tion and on-line implementation, several solutions,
depending on local possibilities have been set up. Of
major interest for improving data accuracy is the progres-
sive use by physicians of the system as a daily aid for
patient care through a web accessible medical record
backed on the database.
Since its creation, RespiRareW has made significant
efforts to collect valuable information on ILD and other
rare lung diseases. Certainly, a major achievement has
been the ability to gather and connect the entire medical
teams involved in the network. Among the tasks in
progress, current efforts include the standardization of
diagnoses and algorithm for explorations in strong
connection with Orphanet, as well as the definition of
minimal datasets that need to be collected for evaluation
of disease progression, and the link with biospecimen
repositories for the development of clinical and research
studies.
Obviously, our database is not a register and presents
multiple selection bias. The fist one is based on the fact
that physicians are responsible for the allocation of
patients and can omit to propose some of them for
inclusion. The second bias is that the participating
physicians are pediatric pulmonologist, who are not
working in intensive care units (ICU). Thus, extremely
severe neonatal or pediatric cases leading to death,
where RespiRareW physicians were not consulted are not
included in the database. In order to improve this bias,
we are currently reinforcing links between pulmonolo-
gists and local ICU physicians. Very mild ILD diseases
can also represent a bias given that they are not always
referred to a reference centre. Finally, children above
15 years old can, in France, be referred to an adult
pulmonologic department. Our pediatric network can
also miss those patients, despite our focused on reinfor-
cing links with adult teams. As a result, our database is
not exhaustive, and cannot at this time provide an
incidence or prevalence. However, we are working hard
to promote the database in France and Europe.
We introduce here the largest national database for
children ILD. Information available in the database
Table 5 Characteristics of sarcoidosis patients
Patient
number






Organs involved (biopsied organ)
1* M 6.5 9.4 42 Lung, lymphadenopathy
2 M 8.0 3.6 48 Lung, lymphadenopathy, eye (uveitis)
3 F 13.8 2 64 Lung, liver
4 M 13.5 3.8 69 Lung, lymphadenopathy, liver
5 M 12.7 4.2 28 Lung, lymphadenopathy
6 F 8.2 2.7 49 Lung, lymphadenopathy, bone marrow, spleen
7 F 7.1 2.4 30 Lung, lymphadenopathy, bowel
8 F 11.2 4 MD Lung, skin
9 M 14.4 3.1 20 Lung, lymphadenopathy, parotid, eye, joints
10 M 5.9 6.7 29 Lung, skin, spleen
11* F 9.1 9.1 59 Lung, lymphadenopathy, liver, eye
12 F 13 3.3 MD Lung, eye, liver, kidney, skin
13 F 11.5 2.6 72 Lung, joints, lymphadenopathy
14 F 10.8 2 12 Lung
15 M 12.8 2.5 18 Lung, liver, skin, eye, bone marrow
16 M 5.6 5.2 MD Lung, larynx, tonsils
17 F 14 4 MD Lung, joints, eye
18 F 9.6 0.8 23 Lung, liver, lymphadenopathy
19 F 8.3 0.4 MD Lung
20 M 9 9.2 50 Lung
21 M 9.3 MD MD Lung, lymphadenopathy, central nervous system
Total Sex ratio 1 Median 9.4 Median3.4 Restricted to the lung=3, multi-organic = 18
* Published patients.
Abbreviations: M: male. F: female. MD: missing data. BAL: broncho-alveolar lavage.
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diagnosis, date of diagnosis, length of follow up, clinical
presentation, BAL, functional tests, genetic tests and
lung biopsy. The number of patient entries is growing
continuously [2]. Our present data confirms similarities
with the 2 other ILD databases in Europe, which are
currently used in Germany and United Kingdom. The
first one reviews all diffuse parenchymal lung diseases
(DPLD) in children in Germany and describes 38 DPLD
children [3]. The calculated incidence was 1.32 cases per
1 million of children per year, which is close to our
estimations. We observe a comparable sex ratio around
0.9 male to female and a large part of onset of disease
before 2 years old (one third before 1 year old in the
German cohort and 42% in this study).
The UK database (BPOLD) focuses on 9 diseases
including ILD, pulmonary alveolar proteinosis, pleural and
pulmonary lymphangiectasia, and idiopathic pulmonary
haemosiderosis. All together, it includes 29 children [4,5].
The described diagnosis breakdown of ILD is similar to the
German study and confirms that the main diagnoses of
ILD are surfactant disorders, haemosiderosis, granuloma-
tous diseases (sarcoidosis) and alveolar proteinosis [1,3].Regarding surfactant disorders, we confirm that
SFTPC mutation I73T (c.218 T>C) is the more preva-
lent mutation, but numerous other mutations have been
described [6,7]. Recently, SFTPC mutations have been
described in an adult cohort of familial idiopathic
fibrosis [8]. This observation together with the extremely
heterogeneous phenotypes of SP-C deficiency, ranging
from early fatal respiratory failure to children and adults
chronic respiratory disease should encourage to enlarge
indications of SFTPC sequencing in children and adults
with chronicle respiratory symptoms and alveolo-
interstitial pattern on CT-scan [7,9-11]. Recessive muta-
tions in the ABCA3 gene were first attributed to fatal
respiratory failure in term neonates but are increasingly
being recognized as a cause of ILD in older children and
young adults [12]. Over 100 ABCA3 mutations have
been identified in neonates with respiratory failure and
in older children with ILD [13-20]. The 5 children we
report here are still alive and the oldest is now 16 years
old. Our 7 diagnosed children for SP-B deficiency died
within the first days of life in a refractory hypoxemia
condition. Mutations in the TITF-1 gene have been
associated with “brain-lung-thyroid syndrome” [21-27].
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which only one is still alive at 5 years old. So far, few
mutations have been reported, mostly in exon 3 [28,29].
The present study reports the largest pediatric
haemosiderosis cohort with 23 cases. Haemosiderosis
is a diagnosis of exclusion of diffuse alveolar haemor-
rhage syndromes (DAH) based on patient presentation
with acute, subacute, or recurrent DAH, on the results
of BAL showing more than 10% siderophages and lung
biopsy showing evidence of ‘bland’ pulmonary haemor-
rhage (i.e., without capillaritis or vascularitis) [1,30].
When diagnosing idiopathic pulmonary haemosiderosis
in a child, particular attention has to be paid to dis-
eases induced by environmental factors such as pesti-
cide and cow’s milk (Heiner’s syndrome) [31]. One
child in our study presented this particular acute situ-
ation. After the initial potential extreme anaemia, out-
come is good in children with steroid treatment. Some
children in our study needed additional hydroxychlor-
oquin treatment as it is recommended for adults’ hae-
mosiderosis. No capillaritis is accounted for in the
database. Vascularitis related ILD are extremely rare in
children, but are probably under-diagnosed. This data-
base is a starting point and enables us to outline miss-
ing data. This dynamic process is ongoing and efforts
are currently made to sensitize physicians to recognize
and to include those patients.
Sarcoidosis represents also a large part of ILD in
children. We report here 21 pediatric sarcoidosis, which
are mostly teenagers. Clinical findings are various,
depending on the different organ involvement [1,32-36].
We also confirm that lung function abnormalities are
frequently observed in children with restrictive pulmonary
pattern and abnormal diffusing capacity [37]. All children
with sarcoidosis were treated with steroids. This probably
highlights that only the most severe sarcoidosis were
included by physicians in the database.
Of importance, the present study highlights that more
than a quarter of ILDs remain with no diagnosis, and
the number is a third for patients included before 2 years
old. This is in agreement with other previous reports.
Undiagnosed cases are heterogeneous in terms of initial
presentation, follow-up and management. An important
challenge is certainly to reduce the number of
unclassified ILDs, especially in youngest children, maybe
with a precise phenotypic description and a better
frequency and observation of lung biopsy. In this
perspective, a more systematic approach to diagnostic is
required, ensuring that the entire appropriate examinations
currently available have been preformed at presentation
and during the follow-up. Although huge efforts have been
made in genomics, the phenotypic description of ILD
cohort is still insufficient [38]. To progress, a well-
implemented database with biologic, functional andhistological markers represents an essential step for a large
phenomic study on pediatric ILD.
To conclude, we introduce here the French network
for rare lung diseases and the first national Internet
based database for pediatric ILD. The database is now
prospectively growing and more accurate data is being
implemented in order to get better phenoms of these
rare lung diseases. Moreover, a biologic bank related to
the web-based database is currently being created. This
database is a great potential for improving patient care
and disease understanding. A European network of phy-
sicians, scientists and families’ foundations is currently
emerging and we are working, together with the US
ChILD foundation on a simplified European database
register as a first step to European large studies [39-41].
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Competence Centres. Legend: PARIS: Reference, Centre Marseille:
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